Yuanyuan Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuanyuan Feng has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Kefan Lin
Dermatology Hospital, Southern Medical University, Guangzhou, China
1 shared publication - Longmei Cai
Department of Radiation Oncology, Southern Medical University, Guangzhou, China
1 shared publication - Yanling Lin
Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
1 shared publication - Yingtong Zhou
Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
1 shared publication - Yuting Chen
First Clinical Medical College, Southern Medical University, Guangzhou 510515, China
1 shared publication
Latest Publications
- Open Access
- 9 April 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (4) , 661
Senescence-Related lncRNA Signature Predicts Prognosis, Response to Immunotherapy and Chemotherapy in Skin Cutaneous Melanoma
Skin cutaneous melanoma (SKCM) is a highly malignant and aggressive cancer. Previous studies have shown that cellular senescence is a promising therapeutic strategy to limit melanoma cell progression. However, models to predict the prognosis of melanoma based on senescence-related lncRNAs and the efficacy of immune checkpoint therapy remain undefined. In this study, we developed a predictive signature consisting of four senescence-related lncRNAs (AC009495.2, U62317.1, AATBC, MIR205HG), and we then classified patients into high- and low-risk groups. GSEA (Gene set enrichment analysis) showed different activation of immune-related pathways in two groups. In addition, there were significant differences between the scores of tumor immune microenvironment, tumor burden mutation, immune checkpoint expression, and chemotherapeutic drug sensitivity between the two groups of patients. It provides new insights to guide more personalized treatment for patients with SKCM.
- 9 April 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (4) , 661
Open AccessSenescence-Related lncRNA Signature Predicts Prognosis, Response to Immunotherapy and Chemotherapy in Skin Cutaneous Melanoma
Skin cutaneous melanoma (SKCM) is a highly malignant and aggressive cancer. Previous studies have shown that cellular senescence is a promising therapeutic strategy to limit melanoma cell progression. However, models to predict the prognosis of melanoma based on senescence-related lncRNAs and the efficacy of immune checkpoint therapy remain undefined. In this study, we developed a predictive signature consisting of four senescence-related lncRNAs (AC009495.2, U62317.1, AATBC, MIR205HG), and we then classified patients into high- and low-risk groups. GSEA (Gene set enrichment analysis) showed different activation of immune-related pathways in two groups. In addition, there were significant differences between the scores of tumor immune microenvironment, tumor burden mutation, immune checkpoint expression, and chemotherapeutic drug sensitivity between the two groups of patients. It provides new insights to guide more personalized treatment for patients with SKCM.